UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline results from the Phase 3 MycarinG study1 evaluating rozanolixizumab,...

Related Keywords

Japan ,Denmark ,Massachusetts ,United States ,Belgium ,Boston ,China ,Canada ,Toronto ,Ontario ,Brussels ,Bruxelles Capitale ,Seanm Healey ,Samantha Masterson ,Natalie Jones ,Antje Witte ,Laurent Schots ,University Health Network ,Brand Communications ,Twitter ,Rare Disease Communications ,University Of Toronto ,Myasthenia Gravis Foundation Of America ,European Union ,Division Of Neurology ,Corporate Communications ,Lancet Reg Health West Pac ,Myasthenia Gravis Activities ,Daily Living ,Professor Vera Bril ,Lead Investigator ,Neuromuscular Section ,Chief Executive Officer ,Myasthenia Gravis Foundation ,Chief Medical Officer ,Generalized Myasthenia Gravis ,Daily Living Profile ,Myasthenia Gravis ,Quantitative Myasthenia Gravis ,Myasthenia Gravis Composite ,Myasthenia Gravis Quality ,Massachusetts General Hospital ,Rare Diseases ,Euronext Brussels ,Disease Communications ,Clinical Overview ,Reg Health West ,Practice Myasthenia ,Test Efficacy ,Accessed November ,Subjects With Generalized Myasthenia Gravis ,Ucb ,